Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Non-Current Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $27.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 362.49% to $27.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.1 million, a 362.49% increase, with the full-year FY2024 number at $5.3 million, up 21.19% from a year prior.
  • Total Non-Current Liabilities was $27.1 million for Q3 2025 at Altimmune, up from $23.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $27.1 million in Q3 2025 to a low of $4.1 million in Q1 2024.
  • A 5-year average of $11.3 million and a median of $8.3 million in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 66.41% in 2022, then soared 362.49% in 2025.
  • Altimmune's Total Non-Current Liabilities stood at $13.6 million in 2021, then plummeted by 66.41% to $4.6 million in 2022, then decreased by 3.99% to $4.4 million in 2023, then rose by 21.19% to $5.3 million in 2024, then skyrocketed by 407.52% to $27.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Total Non-Current Liabilities are $27.1 million (Q3 2025), $23.6 million (Q2 2025), and $5.3 million (Q1 2025).